4.15
0.48%
-0.02
After Hours:
4.15
Pyxis Oncology Inc stock is currently priced at $4.15, with a 24-hour trading volume of 257.31K.
It has seen a -0.48% decreased in the last 24 hours and a -14.08% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.21 pivot point. If it approaches the $4.10 support level, significant changes may occur.
Previous Close:
$4.17
Open:
$4.15
24h Volume:
257.31K
Market Cap:
$244.39M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-1.4613
EPS:
-2.84
Net Cash Flow:
$-77.44M
1W Performance:
-4.38%
1M Performance:
-14.08%
6M Performance:
+190.21%
1Y Performance:
+11.86%
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
617 221 9059
Address
35 Cambridgepark Drive, Suite 100-R, Cambridge
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-02-21 | Initiated | BofA Securities | Neutral |
Nov-02-21 | Initiated | Credit Suisse | Outperform |
Nov-02-21 | Initiated | Jefferies | Buy |
Pyxis Oncology Inc Stock (PYXS) Latest News
William Blair Weighs in on Pyxis Oncology, Inc.'s Q2 2024 Earnings (NASDAQ:PYXS) - Defense World
Defense World
Q2 2024 Earnings Forecast for Pyxis Oncology, Inc. (NASDAQ:PYXS) Issued By William Blair - MarketBeat
MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
MarketBeat
Ratio Examination: Pyxis Oncology Inc (PYXS)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
The Dwinnex
Examining Pyxis Oncology Inc (PYXS) more closely is necessary – US Post News - US Post News
US Post News
Pyxis Oncology Inc Stock (PYXS) Financials Data
Pyxis Oncology Inc (PYXS) Net Income 2024
PYXS net income (TTM) was -$73.79 million for the quarter ending December 31, 2023, a +38.87% increase year-over-year.
Pyxis Oncology Inc (PYXS) Cash Flow 2024
PYXS recorded a free cash flow (TTM) of -$77.44 million for the quarter ending December 31, 2023, a +19.11% increase year-over-year.
Pyxis Oncology Inc (PYXS) Earnings per Share 2024
PYXS earnings per share (TTM) was -$1.84 for the quarter ending December 31, 2023, a +49.59% growth year-over-year.
Pyxis Oncology Inc Stock (PYXS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Connealy Pamela Ann | CFO and COO |
Sep 27 '23 |
Buy |
1.85 |
6,426 |
11,868 |
810,532 |
Wadhane Jitendra | Chief Accounting Officer |
Sep 27 '23 |
Buy |
1.87 |
2,500 |
4,675 |
226,937 |
Connealy Pamela Ann | CFO and COO |
Sep 25 '23 |
Buy |
1.67 |
12,000 |
20,044 |
804,106 |
Wadhane Jitendra | Chief Accounting Officer |
Sep 25 '23 |
Buy |
1.77 |
5,000 |
8,850 |
224,437 |
Connealy Pamela Ann | CFO and COO |
Sep 22 '23 |
Buy |
1.74 |
5,000 |
8,695 |
792,106 |
Wadhane Jitendra | Chief Accounting Officer |
Sep 22 '23 |
Buy |
1.74 |
2,500 |
4,349 |
219,437 |
Sullivan Lara | President and CEO |
Sep 18 '23 |
Sale |
2.10 |
8,541 |
17,936 |
2,403,882 |
Sullivan Lara | President and CEO |
Sep 14 '23 |
Sale |
2.25 |
100 |
225 |
2,412,423 |
Sullivan Lara | President and CEO |
Sep 13 '23 |
Sale |
2.27 |
3,000 |
6,816 |
2,597,265 |
Sullivan Lara | President and CEO |
Sep 12 '23 |
Sale |
2.25 |
4,917 |
11,071 |
2,600,265 |
About Pyxis Oncology Inc
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cap:
|
Volume (24h):